FN1 and ovarian cancer: It was shown that a nine-biomarker diagnostic panel, including fibronectin, could better discriminate ovarian cancers from benign ovarian masses than the OVA1 test (at a threshold sensitivity of 90%, the nine-marker panel gave 88.9% specificity, compared to 63.4% for the OVA1) [39].